Atmo Biosciences appoints world-renowned gastroenterologist Professor Eamonn Quigley as Medical Advisory Board Chair

01 May 2023
www.biospace.com
Executive Change
U.S.-based Professor Quigley brings decades of experience in gastroenterological clinical practice and research as a key opinion leader at the highest levels. Melbourne, Sydney, San Diego - May 1, 2023 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced the appointment of renowned gastroenterologist Professor Eamonn Quigley as Chair of its Medical Advisory Board (MAB). Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas. He is internationally known for his research on gastrointestinal motility disorders, particularly irritable bowel syndrome (IBS) and its link to the gut microbiome. As Atmo MAB Chair, Prof. Quigley will provide leadership and guidance regarding Atmo’s clinical trials portfolio. “I am thrilled to have someone of Professor Quigley’s standing join our MAB as Chair,” said Atmo Biosciences CEO Malcolm Hebblewhite. “Eamonn is an internationally respected leader in gastroenterology. His ongoing research and thought leadership in the areas of motility and Small Intestinal Bacterial Overgrowth (SIBO) will be invaluable as we seek to develop these two key areas of focus in the U.S. and beyond.” Prof. Quigley of the appointment: “I am always excited by the promise of novel technologies that explore the gut microenvironment and the interactions between diet and the microbiome in particular. Atmo’s technology has the potential to serve as a valuable tool in both gastroenterological research and clinical practice. I am looking forward to sharing my insights with the other members of the Board and with Atmo.” Professor Quigley succeeds Professor Peter Gibson. Mr. Hebblewhite commented: “I want to thank Professor Gibson for the considerable contributions he has made to Atmo’s clinical development and the MAB to date. While he is stepping down as Chair, Peter will continue to play an active role with Atmo and the MAB, and I look forward to his ongoing involvement.” About Professor Eamonn M Quigley, MD, FRCP, FACP, MACG, FRCPI Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders, Chief of the Division of Gastroenterology and Hepatology, Medical Director of the Lynda K and David M Underwood Center for Digestive Disorders, and Professor of Medicine, Weill Cornell Medical College at Houston Methodist Hospital, Texas. He is also an Adjunct Professor of Medicine at Texas A and M University. Prior to joining Houston Methodist in 2013, Prof. Quigley was Dean of the Medical School at University College Cork and a principal investigator at the Alimentary Pharmabiotic Center (now Institute). He previously was Professor of Medicine and Chief of Gastroenterology and Hepatology at Nebraska Medical Center in Omaha, Nebraska. He has served as president of both the American College of Gastroenterology and the World Gastroenterology Organization and is a past editor-in-chief of the American Journal of Gastroenterology. He has authored over 1000 publications, mostly in the areas of gut motility, functional gastrointestinal disorders, and gastroesophageal reflux disease (GERD). About Atmo Biosciences: Atmo Biosciences is an Australian digital health business commercializing the world’s first ingestible, gas-sensing capsule which provides insight into gut health and microbiome function. Atmo’s gas-sensing capsule continuously measures clinically important gaseous biomarkers as it travels through the gut. Atmo aims to improve the diagnosis of common functional gut disorders, leading to more personalized treatments and earlier relief of symptoms for sufferers. The gas-sensing capsule is currently being used in research applications in multiple clinical trials around the world. Media Contacts: Atmo Biosciences Contact: Suraya Saleh and Mal Hebblewhite Telephone: +61 3 8803 4649 Email: suraya.saleh@atmobiosciences.com.au
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.